Ethical and Legal Challenges in Resource Allocation for Rare Disease Patients

Kebria Farzaneh, Saman Eskandar, Hamid Mohammadikojidi

Abstract


Rare diseases, defined as conditions affecting fewer than 5 per 10,000 individuals, present unique ethical and legal challenges in healthcare resource allocation. Despite legislative advancements like the Orphan Drug Act (ODA), systemic barriers persist, including high treatment costs, limited access, and inequitable distribution of resources. This paper examines the ethical and legal dilemmas in allocating resources to rare disease patients, evaluates global frameworks, and proposes actionable solutions to balance equity, cost-effectiveness, and justice. A comprehensive review of literature, legislative policies, and economic evaluations was conducted, focusing on rare disease definitions, orphan drug development, and resource allocation models. Key challenges include economic disincentives for pharmaceutical investment, ethical conflicts between individual rights and collective welfare, and fragmented international classification systems. Solutions such as multi-criteria decision analysis (MCDA), expanded orphan drug legislation, and centralized reference networks are discussed. A hybrid approach integrating ethical principles, economic pragmatism, and global collaboration is essential to ensure equitable care for rare disease patients.

Keywords


Rare diseases, Resource allocation, Medical ethics, Orphan drugs, Health equity

Full Text:

Full Text

References


Ludlow, P. The European Commission.

The New European Community, Routledge:

; 85-132.

Philippidis, A. Orphan drugs, big pharma.

Human Gene Therapy. 2011; 22(9): 1037-1040.

Wamelink, M. M., et al. The difference

between rare and exceptionally rare: molecular

characterization of ribose 5-phosphate isomerase

deficiency. Journal of Molecular Medicine.

; 88: 931-939.

O'Connor, D. J. Orphan drug

designation–Europe, the USA and Japan. Expert

Opinion on Orphan Drugs. 2013; 1(4): 255-259.

Gammie, T., et al. Access to orphan

drugs: a comprehensive review of legislations,

regulations and policies in 35 countries. PloS

One. 2015; 10(10): e0140002.

Abbasi, M. & Faraji, O. Role of ethics in

fair allocation of health resources. 2013; 121-

Yousefi, M., et al. Methods of resource

allocation based on needs in health systems, and

exploring the current Iranian resource allocation

system. Hakim Journal. 2010; 13(2): 80-90.

Duchange, N., et al. Ethical management

in the constitution of a European database for

leukodystrophies rare diseases. European Journal

of Paediatric Neurology. 2014; 18(5): 597-603.

Kacetl, J., et al. Ethical Questions Linked

to Rare Diseases and Orphan Drugs–A

Systematic Review. Risk Management and

Healthcare Policy: 2020; 2125-2148.

Lenaerts, K. Exploring the limits of the

EU charter of fundamental rights. European

Constitutional Law Review. 2012; 8(3): 375-403.

Hews‐Girard, J., et al. Objectivity in rare

disease research: a philosophical approach.

Nursing Inquiry. 2020; 27(1): e12323.

Rodriguez-Monguio, R., et al. Ethical

imperatives of timely access to orphan drugs: is

possible to reconcile economic incentives and

patients’ health needs? Orphanet Journal of Rare

Diseases. 2017; 12(1): 1-8.

Hyde, R. & Dobrovolny, D. Orphan drug

pricing and payer management in the United

States: are we approaching the tipping point?

American Health & Drug Benefits. 2010; 3(1):

Tambuyzer, E. Rare diseases, orphan

drugs and their regulation: questions and

misconceptions. Nature Reviews Drug

Discovery. 2010; 9(12): 921-929.

Force, U. P. S. T., et al. Guide to Clinical

Preventive Services. U.S. Department of Health

and Human Services.1996.

World Health Organization. International

Classification of Diseases. 9th Revision.1978.

Haffner, M. E. Adopting orphan drugs—

two dozen years of treating rare diseases. New

England Journal of Medicine. 2006; 354(5): 445-

Wästfelt, M., et al. A journey of hope:

lessons learned from studies on rare diseases and

orphan drugs. Journal of Internal Medicine.

; 260(1): 1-10.

Bank, I., et al. Social aspects of genetic

testing for factor V Leiden mutation in healthy

individuals and their importance for daily

practice. Thrombosis Research. 2004; 113(1): 7-

Schieppati, A., et al. Rare diseases: a

global challenge. The Lancet. 2008; 371: 2039-

Dehnavieh, R., et al. Challenges of

determining basic health insurance package in

Iran. Payesh (Health Monitor). 2011; 10(2): 273-

Barham, L. Three NICE thresholds for

cost-effectiveness: does that make sense.

Pharmaphorum. 2016; 25.

Czech, M., et al. A review of rare disease

policies and orphan drug reimbursement systems

in 12 Eurasian countries. Frontiers in Public

Health. 2020; 7: 416.

Farzaneh et al

et al

Farzaneh et al

| J Iran Sci Asso Med Ethi, 2025, Volume 1, Issue 1

Roberts, M., et al. Conceptualizing a

model: a report of the ISPOR-SMDM modeling

good research practices task force–2. Medical

Decision Making. 2012; 32(5): 678-689.

Thokala, P., et al. Multiple criteria

decision analysis for health care decision

making—an introduction: report 1 of the ISPOR

MCDA Emerging Good Practices Task Force.

Value in Health. 2016; 19(1): 1-13.

Moradi, N., et al. Willingness to pay for

one quality-adjusted life year in Iran. Cost

Effectiveness and Resource Allocation. 2019;

(1): 1-10.

Simoens, S. Health technologies for rare

diseases: does conventional HTA still apply?

Expert Review of Pharmacoeconomics &

Outcomes Research. 2014; 14(3): 315-317.

Bravi, F., et al. Hospital network

performance: A survey of hospital stakeholders’

perspectives. Health Policy. 2013; 109(2): 150-

Mobinizade, M. & Fakoorfard, Z.

Allocation of resources for diagnostic and

therapeutic interventions in rare diseases. Health

Technology Assessment in Action. 2021.

Gericke, C. A., et al. Ethical issues in

funding orphan drug research and development.

Journal of Medical Ethics. 2005; 31(3): 164-

McCabe, C., et al. Orphan drugs and the

NHS: should we value rarity? BMJ. 2005;

(7523): 1016-1019.

Pinxten W, Denier Y, Dooms M,

Cassiman JJ, Dierickx K. A fair share for the

orphans: ethical guidelines for a fair distribution

of resources within the bounds of the 10-yearold European Orphan Drug Regulation. Journal

of Medical Ethics. 2012; 38(3):148-53.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 Kebria Farzaneh, Saman Eskandar, Hamid Mohammadikojidi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.